We are live on ! Find out more
VMD icon

Viemed Healthcare

104 hedge funds and large institutions have $184M invested in Viemed Healthcare in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more call options, than puts

Call options by funds: $12K | Put options by funds: $5K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

16% more capital invested

Capital invested by funds: $159M → $184M (+$25.6M)

0.34% less ownership

Funds ownership: 61.31%60.97% (-0.34%)

7% less funds holding

Funds holding: 112104 (-8)

16% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 37

40% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 20

Holders
104
Holders Change
-8
Holders Change %
-7.14%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
12
Increased
31
Reduced
37
Closed
20
Calls
$12K
Puts
$5K
Net Calls
+$7K
Net Calls Change
+$3K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.15M -$211K -29,063 -17%
PAM
27
Panagora Asset Management
Massachusetts
$1.1M +$413K +56,964 +69%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$1.1M -$24.6K -3,393 -2%
Arrowstreet Capital
29
Arrowstreet Capital
Massachusetts
$990K -$593K -81,741 -39%
SFM
30
Spartan Fund Management
Canada
$983K +$909K +125,240 New
N
31
Nuveen
North Carolina
$849K
LCM
32
Legato Capital Management
California
$777K
TPM
33
Triasima Portfolio Management
Quebec, Canada
$753K -$2.18M -301,137 -76%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$751K -$2.31M -318,058 -77%
Two Sigma Advisers
35
Two Sigma Advisers
New York
$713K -$179K -24,700 -21%
RC
36
RBF Capital
California
$628K
PCM
37
Perritt Capital Management
Illinois
$620K
Charles Schwab
38
Charles Schwab
California
$615K +$2.68K +369 +0.5%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$611K -$5.16K -711 -0.9%
CAM
40
Claret Asset Management
Quebec, Canada
$592K +$218 +30 +0%
PM
41
Penbrook Management
New York
$548K -$3.27K -450 -0.6%
SO
42
STRS Ohio
Ohio
$547K -$47.9K -6,600 -9%
VCP
43
Verus Capital Partners
Arizona
$535K +$18.3K +2,525 +4%
Two Sigma Investments
44
Two Sigma Investments
New York
$531K -$509K -70,133 -51%
TWC
45
TD Waterhouse Canada
Ontario, Canada
$507K +$87.6K +12,079 +28%
SRCM
46
Sage Rock Capital Management
New York
$412K +$47.2K +6,500 +14%
Bank of America
47
Bank of America
North Carolina
$386K +$125K +17,280 +54%
Barclays
48
Barclays
United Kingdom
$372K +$297K +40,930 +636%
CIC
49
Cornercap Investment Counsel
Georgia
$372K
Invesco
50
Invesco
Georgia
$348K -$177K -24,449 -36%

VMD Hedge Fund Activity: Q4 2023 in Review

104 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Viemed Healthcare (VMD) for Q4 2023, worth a combined $184M — up 16% from $159M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of VMD and 12 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 31 added.

The largest buyer was Morgan Stanley, adding an estimated $2.45M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $2.31M.

  • 104 institutional investors held Viemed Healthcare (VMD) as of Q4 2023, down from 112 in Q3 2023.
  • Funds reported $184M of Viemed Healthcare stock for Q4 2023, up 16% quarter-over-quarter.
  • 12 funds opened new Viemed Healthcare positions in Q4 2023 and 20 closed out, a net change of -8 holders.
  • The largest Viemed Healthcare buyer in Q4 2023 was Morgan Stanley, an estimated $2.45M added.
  • The largest Viemed Healthcare seller in Q4 2023 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2023.